CURRENT ISSUE
July, 2026
No. 111 (7)
2025 Impact Factor: 8.2
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
EDITOR'S PICKS
Review Series
Introduction to the Review Series. Chronic myeloid leukemia in 2026
Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission
Is there a best frontline therapy in chronic myeloid leukemia?
Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses
Intrinsic cellular resistance to BCR::ABL1 inhibitors
Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing
Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission
ARTICLES IN THREE SENTENCES
Article
Interleukin signaling mitigates the inhibitory effects of combined Src/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) relies on BCR-ABL1 signaling and is commonly treated with tyrosine kinase inhibitors. Naeemikia and colleagues investigated the impact of combined Src/BCR-ABL1 inhibition on T-cell function using experimental models of Ph+ ALL. They demonstrated that interleukin signaling rescues T-cell activation impaired by kinase inhibition, revealing a mechanism that may help maintain antileukemic immunity during treatment.
Letter
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe
Relapsed or refractory multiple myeloma remains a major therapeutic challenge, particularly for patients in whom standard treatment options have failed. Cavo and colleagues assessed the real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated across European centers. They found that belantamab mafodotin achieved clinically meaningful responses with a manageable safety profile in routine practice, supporting its role as a treatment option for heavily pretreated patients.
Letter
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy associated with poor outcomes and limited treatment options. Pemmaraju and colleagues evaluated the long-term efficacy of first-line tagraxofusp in adult patients with BPDCN across different fitness and frailty categories. They found that tagraxofusp induced durable responses and prolonged survival regardless of the patients level of fitness, supporting its use as an effective frontline therapy in a broad BPDCN population.
Article
Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia
Aplastic anemia is an immune-mediated bone marrow failure syndrome commonly treated with immunosuppressive therapy based on horse anti-thymocyte globulin (ATG). Pool and colleagues investigated the immunological effects of horse ATG-based therapy by analyzing changes in lymphocyte populations. They found that selective depletion of specific lymphocyte subsets underlies the clinical efficacy of horse ATG, providing new insights into the immune mechanisms responsible for hematologic recovery.
TAKE ADVANTAGE FROM HAEMATOLOGICA
